--- title: "U.S. Stock Market Midday Update: CDIO Rises 13.11% Without Positive News? Capital Inflows Drive Volatility" type: "News" locale: "en" url: "https://longbridge.com/en/news/295695074.md" description: "Cardio Diagnostics rose 13.11%; AbbVie fell 1.09%, with a transaction volume of USD 419 million; Gilead Sciences rose 0.11%, with a transaction volume of USD 343 million; Biovie rose 36.22%, with a transaction volume of USD 312 million; Amgen rose 0.28%, with a market capitalization of USD 224.6 billion" datetime: "2026-08-12T17:38:20.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/295695074.md) - [en](https://longbridge.com/en/news/295695074.md) - [zh-HK](https://longbridge.com/zh-HK/news/295695074.md) generator: "portal-rs" --- # U.S. Stock Market Midday Update: CDIO Rises 13.11% Without Positive News? Capital Inflows Drive Volatility **U.S. Stock Market Midday Update** Cardio Diagnostics, up 13.11%, with increased trading volume and no significant news recently. The trading is active, with clear capital flow. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. **Stocks with High Trading Volume in the Industry** AbbVie down 1.09%. Based on recent key news: 1. On August 10, AbbVie announced the acquisition of Apogee at $135.11 per share, totaling approximately $10.9 billion, aimed at expanding its immunology product portfolio, driving stock price volatility. 2. On August 11, Evercore ISI raised AbbVie's target price from $246 to $260, reflecting market confidence in its future growth. 3. On August 12, AbbVie's neuroscience product portfolio accelerated development, providing new growth momentum, and the market's underestimation of its potential may affect the stock price. The industry shows significant growth potential, with active capital inflow. Gilead Sciences up 0.11%. Based on recent key news: 1. On August 4, Gilead Sciences reported a quarterly loss of $6.75 per share, better than analysts' expectations of a $7.24 loss, with quarterly sales reaching $7.803 billion, exceeding the expected $7.4 billion, driving the stock price up. 2. On August 11, Gilead Sciences successfully acquired Ouro Medicines, aiming to develop a breakthrough T-cell engager, which could become the first and most effective drug of its kind, enhancing market confidence. 3. On August 12, MacroGenics announced it received a $10 million milestone payment from Gilead Sciences based on its licensing agreement for a preclinical bispecific project, further driving the stock price up. The biopharmaceutical industry has performed strongly recently, with noticeable capital inflow. Biovie, up 36.22%, with trading volume reaching $312 million and increased trading volume, and no significant news recently. The trading is active, with clear capital flow. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. **Stocks with High Market Capitalization in the Industry** Amgen up 0.28%, with increased trading volume. Based on recent key news: 1. On August 11, BeiGene announced that the jointly developed Antibody Drug Conjugate (ADC) with Amgen has officially entered clinical use, covering 80 cities nationwide and over 200 medical institutions. This news boosted Amgen's stock price. 2. On August 10, Amgen focused resources on its core dual-target project MariTide, launching multiple clinical projects covering obesity, type 2 diabetes, cardiovascular risk, and sleep apnea. The progress of this project has enhanced market confidence in Amgen's future growth. 3. On August 12, Amgen's annualized return over the past 15 years was 14.88%, significantly outperforming the market average. The long-term stable performance has attracted more investor attention. The biotechnology industry has performed strongly recently, with noticeable capital inflow ### Related Stocks - [CDIO.US](https://longbridge.com/en/quote/CDIO.US.md) - [ABBV.US](https://longbridge.com/en/quote/ABBV.US.md) - [GILD.US](https://longbridge.com/en/quote/GILD.US.md) - [BIVI.US](https://longbridge.com/en/quote/BIVI.US.md) - [AMGN.US](https://longbridge.com/en/quote/AMGN.US.md) ## Related News & Research - [Gilead Sciences (NASDAQ:GILD) CEO Sells 15,000 Shares of Stock](https://longbridge.com/en/news/297831169.md) - [Hyatt Hotels (H) Could Be 13% Below Fair Value After New Shelf Registration](https://longbridge.com/en/news/297517419.md) - [16:13 ETJohn Hancock Closed-End Funds Declare Quarterly Distributions](https://longbridge.com/en/news/297693169.md) - [Jazz Pharmaceuticals (JAZZ) Could Be 13% Undervalued On FDA Approval Of Ziihera](https://longbridge.com/en/news/297431759.md) - [REG - FIL Limited SEGRO PLC Prologis, Inc. - Form 8.3 - PROLOGIS INC](https://longbridge.com/en/news/297794087.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**